These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 9174799)

  • 21. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lovastatin to prevent acute coronary events with average cholesterol levels.
    MacFarlane LL; Carek PJ
    J Fam Pract; 1998 Aug; 47(2):91-2. PubMed ID: 9722787
    [No Abstract]   [Full Text] [Related]  

  • 23. Hypercholesterolemia: a reversible risk factor for coronary heart disease.
    Mishkel MA
    CMAJ; 1989 Feb; 140(4):419. PubMed ID: 2644008
    [No Abstract]   [Full Text] [Related]  

  • 24. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A need to redefine the consensus on the use of statins in coronary heart disease prevention.
    Fruchart JC
    Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008
    [No Abstract]   [Full Text] [Related]  

  • 26. Guidelines for cholesterol management: recommendations of the National Cholesterol Education Program's Adult Treatment Panel II.
    Grundy SM
    Heart Dis Stroke; 1994; 3(3):123-7. PubMed ID: 8044423
    [No Abstract]   [Full Text] [Related]  

  • 27. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The effect of ethyl-chlorophenoxyisobutyrate on the serum lipids in coronary sclerosis].
    Keller L; Rétsági G; Sebestyén M; Diczendy S; Erdélyi G
    Z Gesamte Inn Med; 1966 Mar; 21(6):169-72. PubMed ID: 5988081
    [No Abstract]   [Full Text] [Related]  

  • 29. Lipid lowering agents. How important are they in secondary prevention of coronary heart disease?
    Colquhoun DM
    Aust Fam Physician; 2002 Jan; 31(1):25-6, 29-30. PubMed ID: 11840884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The reality of treating dyslipidaemia in patients with coronary heart disease: a primary care survey.
    Wright DJ; Grayson AD; Jackson M; Dainty C
    Int J Clin Pract; 2003; 57(6):488-91. PubMed ID: 12918888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease.
    Nag SS; Pearson TA; Ma L; Landsman PB; Cimino A; Vickers FF; Alexander CM; Melin JM
    Am J Cardiol; 2005 Apr; 95(7):862-4. PubMed ID: 15781017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention and treatment of arteriosclerosis.
    DePalma RG
    Compr Ther; 1992 Feb; 18(2):30-2. PubMed ID: 1547601
    [No Abstract]   [Full Text] [Related]  

  • 33. Rationale for use of lipid-lowering drugs.
    Dayton S
    Fed Proc; 1971; 30(3):849-56. PubMed ID: 5575297
    [No Abstract]   [Full Text] [Related]  

  • 34. Evidence based hypolipidaemic drug treatment.
    Mant A
    Aust Fam Physician; 2000 Jan; 29(1):58-9. PubMed ID: 10721547
    [No Abstract]   [Full Text] [Related]  

  • 35. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation.
    Jaeger BR; Meiser B; Nagel D; Uberfuhr P; Thiery J; Brandl U; Brückner W; von Scheidt W; Kreuzer E; Steinbeck G; Reichart B; Seidel D
    Circulation; 1997 Nov; 96(9 Suppl):II-154-8. PubMed ID: 9386091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment and prevention of coronary heart disease].
    Coelho E
    J Med (Oporto); 1965 Oct; 58(184):189-202. PubMed ID: 5215283
    [No Abstract]   [Full Text] [Related]  

  • 37. [Secondary prevention in patients with a coronary disorder: wider indication for cholesterol-lowering drugs].
    Peters RJ
    Ned Tijdschr Geneeskd; 1995 Mar; 139(12):604-6. PubMed ID: 7700402
    [No Abstract]   [Full Text] [Related]  

  • 38. Is cholesterol testing/treatment really beneficial?
    Barratt A; Irwig L
    Med J Aust; 1993 Nov; 159(10):644-7. PubMed ID: 8232004
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of prodectin and lipoic acid on the lipid metabolism indicators in chronic ischemic heart disease].
    Grigor'ian VA; Klantsa NA; Prishliak VD; Klantsa PN
    Vrach Delo; 1981 Oct; (10):13-5. PubMed ID: 6795820
    [No Abstract]   [Full Text] [Related]  

  • 40. [Regression of coronary sclerosis].
    Trenkwalder P; Lydtin H
    Dtsch Med Wochenschr; 1991 Mar; 116(11):438-9. PubMed ID: 2001659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.